Erratum to: The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-Blind Trial in Patients with Hypertension (Advances in Therapy, (2013), 30, 12 (1086-1099), 10.1007/s12325-013-0076-6);The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: A randomized, double-blind trial in patients with hypertension

Advances in Therapy

Volumn 30, Issue 12, 2013, Pages 1086-1099

  Ruilope, Luis ^a,b   Schaefer, Angie ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

Angiotensin II receptor antagonist; Angiotensin converting enzyme inhibitor; Calcium channel blocker; Cardiology; Central systolic blood pressure; Fixed dose combination; Non invasive CV analysis system; Uncontrolled hypertension

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS PERINDOPRIL; ANGIOTENSIN 2 RECEPTOR; HYDROCHLOROTHIAZIDE; PERINDOPRIL; UNCLASSIFIED DRUG; AMLODIPINE, PERINDOPRIL DRUG COMBINATION; DRUG COMBINATION; IMIDAZOLE DERIVATIVE; OLMESARTAN; TETRAZOLE DERIVATIVE;

ADULT; AORTA PRESSURE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRONCHITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; ERECTILE DYSFUNCTION; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PERIPHERAL EDEMA; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERINDOPRIL; RISK ASSESSMENT; TETRAZOLES; TREATMENT OUTCOME;

EID: 84890556957     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0186-4     Document Type: Erratum

References (25)

1. Sharman JE, Laurent S. Central blood pressure in the management of hypertension: soon reaching the goal? J Hum Hypertens. 2013;27:405-11.
2. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-25.
3. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
4. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219.
5. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
6. Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens. 2007;25:1327-36.
7. Malacco E, Omboni S, Volpe M, Auteri A, Zanchetti A. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. J Hypertens. 2010;28:2342-50.
8. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs. 2008;68:1239-72.
9. Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29:11-25.
10. Chrysant S, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587-604.
11. ® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: rationale and design of the SEVITENSION study. Contemp Clin Trials. 2011;32:710-6.
12. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-87.
13. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension task force document. J Hypertens. 2009;27:2121-58.
14. Committee for Proprietary Medicinal Products (CPMP). Points to consider on switching between superiority and non-inferiority (CPMP/EWP/482/99). 2000: European Agency for the Evaluation of Medicinal Products. http://www.emea. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003658. pdf. Accessed Nov 14, 2013.
15. Omboni S, Malacco E, Mallion JM, Volpe M, Zanchetti A, Study G. Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies. J Hypertens. 2012;30:1468-77.
16. Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension. 2001;38:932-7.
17. O'Rourke MF, Pauca AL. Augmentation of the aortic and central arterial pressure waveform. Blood Press Monit. 2004;9:179-85.
18. Wang KL, Cheng HM, Chuang SY, et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens. 2009;27:461-7.
19. Oliveras A, Garcia-Ortiz L, Segura J, et al. Association between urinary albumin excretion and both central and peripheral blood pressure in subjects with insulin resistance. J Hypertens. 2013;31:103-8.
20. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50:197-203.
21. Pini R, Cavallini MC, Palmieri V, et al. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol. 2008;51:2432-9.
22. Williams B, Lacy PS. Central aortic pressure and clinical outcomes. J Hypertens. 2009;27:1123-5.
23. Liu L, Zhang Y, Liu G, et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157-72.
24. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049-51.
25. Pepine CJ, Kowey PR, Kupfer S, et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol. 2006;47:547-51.